加载中
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
收盘时
US$39.49
−US$1.35 · -3.31%
盘后
US$39.49
US$0.00 · 0.00%
10月13日 16:15 ET
盘中时间采用ET。市场数据可能有所延迟。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日内区间
当前US$39.49
52周区间
当前US$39.49
盘中时间采用ET。市场数据可能有所延迟。
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
日内区间
当前US$39.49
52周区间
当前US$39.49
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年2月24日 | 1:4 | — | — |
已生效 2023年2月24日
1:4
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM6100.17万0.08%787.4亿 USD0.19%US$276.71-0.43%
iShares Russell 2000 Growth ETFIWO2195.71万0.16%139.17亿 USD0.24%US$351.1-0.74%
iShares Biotechnology ETFIBB1930.7万0.18%108.2亿 USD0.44%US$200.02-2.08%
Dimensional - US Small Cap ETFDFAS1447万0.04%338.04亿 USD0.31%US$78.33+0.20%
Vanguard Russell 2000 ETFVTWO1425.52万0.08%180亿 USD0.06%US$111.77-0.45%
Schwab U.S. Small-Cap ETFSCHA1371.52万0.06%217.13亿 USD0.03%US$32.56-0.31%
iShares U.S. Pharmaceuticals ETFIHE903.25万0.58%15.52亿 USD0.37%US$97.36-2.82%
Vanguard Health Care ETFVHT852万0.04%220亿 USD0.09%US$316.37-1.34%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
